Drug Trial Radar · NCT05440799
A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479
Last checked: Nov 20, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
Jul 20, 2022
Primary completion
Aug 2, 2023
Study completion Aug 2, 2023
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jul 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 67 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1819479 in healthy female subjects of non-childbearing potential.
Conditions
- Healthy
Interventions
BI 1819479Drug
BI 1819479
BI matching placeboDrug
BI matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigatorTime frame: up to 106 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CRS Clinical Research Services Mannheim GmbH
Mannheim, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.